Peer-influenced content. Sources you trust. No registration required. This is HCN.

FDA Approves Selpercatinib as First Therapy for Certain Patients With Lung, Thyroid Cancers

Based on the results of an open-label trial, selpercatinib (Retevmo) becomes the first targeted therapy to be granted accelerated approval by the FDA for use in patients with cancer who have certain tumors that have an alteration (mutation or fusion) in the RET gene.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form